A Randomized, Double-Blind, Placebo-Controlled Phase II Study of DAS181 in Patients With Parainfluenza Infection.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2018
At a glance
- Drugs DAS 181 (Primary)
- Indications Parainfluenza virus infections
- Focus Adverse reactions
- 06 Jul 2017 Planned primary completion date changed from 30 Jun 2014 to 27 Feb 2014.
- 29 Sep 2011 New trial record